The 10 most active investment institutions in 2017

Source: huoshichuang 2018-02-05 at the second China Medical and health Entrepreneurs Conference held by huoshichuang on December 2, 2017, huoshichuang released the list of "top 10 most active investment institutions in China's life and health industry in 2017" The list is based on the data platform of intelligent investment consulting system created by flint, and data is collected by means of questionnaire, interview and telephone interview It is analyzed and screened from the number of investment cases, investment amount, number of exit cases and media exposure index in the field of life and health in 2017, and finally selected based on detailed data, real market and scientific standards Top 10 The total investment amount of the listed investment institutions is 17.652 billion yuan, with 189 investment projects and 35 projects withdrawn In 2017, the most active investment institutions in China's life and health industry: Gao Tejia, Honghui capital, Sequoia Capital China fund, Huagai capital, Junlian capital, Ping An venture capital, Puhua capital, Qiming venture capital, Shenzhen Venture Capital, Zhongwei Fund (ranked in no particular order, listed in ascending alphabetical order) Gao Tejia In 2001, gaotejia investment group was established in Shenzhen, focusing on investment in medical and health industry, taking strategic equity investment as the leading role, covering all stages of investment business such as M & A, PE, VC, angel, etc The asset management scale of gaotejia investment group is 20.6 billion yuan, and there are 24 medical and health industry funds It has successively invested in more than 130 enterprises, including more than 60 medical and health enterprises, and promoted the successful listing of 10 enterprises, among which the holding investment in Boya biology, the leading domestic blood products enterprise, and promoted its successful listing Among the successful investment cases in the field of medical and health care, they mainly include Boya biology, sinomedi, Mindray medical, anouta, tianguangshi, Zhijiang biology, ruiang biology, boassi, Shengxiang biology, etc sinomedi and anouta are both representative enterprises in the domestic gene industry, and Mindray medical, Zhijiang biology and tianguangshi are also domestic medical equipment , molecular diagnosis, monoclonal antibody and other fields of leading enterprises Honghui capital Honghui capital was founded in 2014 It is an investment fund focusing on the medical and health industry It invests in different stages of enterprise growth with managed US dollars and RMB funds Based on the medical and health industry, Honghui capital focuses on medical services, mobile medicine, medical devices (including imaging equipment, diagnostic reagents and medical consumables), biopharmaceuticals (chemical drugs, biological drugs and biological agents) The investment cases of Honghui capital mainly include Wentai technology, development of pharmaceutical industry, interesting hospital, Jikai gene, Makong dentistry, Huidu medical, etc., covering three parts: drugs, medical devices and medical services Sequoia Capital China fund Sequoia Capital China fund, as the "entrepreneur behind the entrepreneur", focuses on investment opportunities in technology / media, health care, consumer goods / services, and industrial technology In the past 12 years, Sequoia Capital China fund has invested in more than 300 enterprises including Alibaba Among them, in the field of medical and health care, Sequoia Capital China fund has invested in Huada gene, zaiding medicine, Weigao group, registration network, Yuyue medicine, Beida medicine, Huoshi medicine and other well-known enterprises in China, among which Huada gene, zaiding medicine, Yuyue medicine and so on are all listed companies, and Huoshi medicine, micro medicine (original registration network) and so on are all listed companies Become a unicorn enterprise in the field of life and health in China Founded in 2012, Huagai capital is a private equity investment institution co founded by a group of professionals from well-known investment institutions in the industry at home and abroad, focusing on the private equity investment business in the Chinese market At present, it manages multiple equity investment funds, such as medical fund, TMT fund, cultural fund, etc., with an asset management scale of nearly 10 billion yuan, mainly invested in the start-up or growth stage companies in the three fields of medical health, TMT and culture Huagai capital mainly invests in leading enterprises in biomedicine, medical devices, medical services and other sub sectors in the field of medical and health care Focus on growth / M & A enterprises, make equity / holding investment, invest in a small number of high-quality early projects, cultivate early project sources, and obtain excellent returns The main investment cases of Huagai capital in the field of medical and health include doctor's glasses, Fe3, Fuhong Hanlin, Guanxin software, Hannan Zhonghe, Kangtai biology, Rendu biology, Xiangyi pension, zhengguangxing, etc., covering antibody drugs, health information software, peptide drugs, vaccines, molecular diagnosis, pension, medical services and other fields Among them, Fuhong Hanlin, Kangtai biology and Rendu biology are the representative enterprises of monoclonal antibody, hepatitis B vaccine and RNA molecular diagnosis respectively Junlian capital, the predecessor of Junlian capital, is Lenovo investment, an independent professional venture capital company owned by Lenovo holdings It was founded in April 2001, with $35 million held by Lenovo as the first phase fund In February 2012, Lenovo investment changed its name to Junlian capital Junlian capital's core business is venture capital in the initial stage and growth investment in the expansion stage At present, Junlian capital is in charge of USD and RMB funds with a total scale of more than 35 billion yuan, focusing on China's innovation and growth opportunities As of 2017, there are more than 300 enterprises invested by Junlian capital, 60 of which have been successfully listed / listed at home or abroad, and nearly 50 enterprises have exited through M & A The investment cases of Junlian capital in the field of medical health include Rabo biology, Paige biology, Cinda biology, Berek and Kang, Mingde biology, Nuofei health, yaomingkant, Jinyu medicine, etc Among them, Beirui Hekang is one of the leaders in the field of gene in China, which has been backdoor listed; Mingde biology is a leading enterprise in the field of in vitro diagnosis, which has been listed on the new third board; Jinyu medicine is also a leading enterprise in the field of third-party testing in China In 2012, Ping An insurance (Group) Co., Ltd invested 1 billion of its own funds to establish Ping An Innovation Investment Fund After 5 years of operation, Ping An venture capital has become a specialized equity investment institution in the field of innovation since the beginning, raising and managing more than 10 billion yuan Ping An Innovation Investment Fund covers the whole stage of investment, focusing on the investment in the middle and later stages and in the listed company pipe In the investment cases of Ping An venture capital in the field of medical and health, there are companies focusing on molecular diagnosis and early screening technology, such as decoded DNA, China conatai, etc there are also many health management and information platforms with media attributes, such as palm sugar medicine, purple medicine, transformation medicine network, health industry, and health knowledge network In addition, Ping An venture capital has also participated in overseas projects such as gluense, Rani therapeutics and ativa Founded in 2004, PwC capital is a professional equity investment institution focusing on early and medium-term projects Over the years, PricewaterhouseCoopers has invested in more than 300 excellent start-ups, and achieved phased results in the growth process of more than 30 enterprises Puhua capital currently manages several company and limited partnership equity investment funds, including Zhejiang Puhua tianqin equity investment partnership (limited partnership), Zhejiang tianqin equity investment partnership (limited partnership), Zhejiang Puhua Kehua equity investment partnership (limited partnership), etc as of March 2017, the capital under management is 11 billion yuan, which is well-known in Zhejiang Province And the family At present, PwC capital's main businesses include private equity investment (including VC and PE), financial (financing) consulting, investment consulting, M & A and other investment banking businesses, focusing on potential leading enterprises in TMT, consumer industry, service industry, energy conservation and environmental protection, modern agriculture, publishing and media, new energy, medicine and medical, advanced manufacturing and other fields, including start-up period, growth period Maturity period, pre IPO stages In the field of medical and health care, PwC has invested in many projects, such as Hu qingyutang, remebot, aijitaikang, cognitive care, mcditou, etc Qiming venture capital focuses on investing in early and growing excellent enterprises in industries such as Internet consumption, healthcare, information technology and clean technology Up to now, Qiming has invested in more than 210 enterprises, of which more than 30 have been listed on the NYSE, NASDAQ, Hong Kong stock exchange, Taiwan counter buying center, Shanghai stock exchange a share and Shenzhen Stock Exchange respectively or won investment returns through M & A Among the investment cases in the field of medical and health care, well-known enterprises include tiger pharmaceutical, Ganli pharmaceutical, zaiding pharmaceutical, toujing life, Eide biology, micro medical group, etc Shenzhen Venture Capital Shenzhen Innovation Investment Group Co., Ltd (hereinafter referred to as "Shenzhen Venture Capital") is a limited liability company established by Shenzhen Municipal Government in 1999, which is specialized in venture capital At present, its registered capital is 4.2 billion yuan, and the total scale of various funds under management is about 265.624 billion yuan Shenzhen Venture Capital mainly invests in small and medium-sized enterprises, independent innovation high-tech enterprises and emerging industry enterprises, start-up and growth period, transformation and upgrading enterprises, covering information technology, Internet / new media, biomedicine, new energy / energy conservation and environmental protection, chemical industry / new materials, high-end equipment manufacturing, consumer goods / modern services and other industries supported by national policies In the field of biology / medicine, Shenzhen Venture Capital has participated in the investment projects of BGI, Shenzhen Mindray biology, kangfang biology, cutting-edge biology, SAIJIN biology, Shanghai minimally invasive, etc Zhongwei fund, sponsored by Tianyi investment group, is a professional fund dedicated to medical and health investment It is also the first medical venture capital fund in China to obtain the investment and participation of national development and Reform Commission and Shanghai municipal government guiding fund at the same time As the strategic investment platform of the group, Zhongwei fund, relying on the huge chain network and population base of meinian health, has made layout in the fields of medical devices, medical services, medical informatization, personalized medical treatment, etc., with a management fund scale of 3 billion yuan Zhongwei fund has invested in many industry star enterprises including meinian health, yaomingkant, Zhicheng biology, Hejian biology, Suzhou Langrun, Jiangsu Kangzhong, Minsheng Otolaryngology, Kangda international, Xiamen intelligent industry, Beijing huaketai, happy oral